Grilinctus-BM Paediatric Syrup is a combination medication containing Terbutaline (1.5 mg/5 ml) and Bromhexine (4 mg/5 ml), formulated specifically for pediatric use to manage respiratory conditions characterized by bronchospasm and excessive mucus production. Terbutaline, a selective beta-2 adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating easier breathing in conditions such as asthma, bronchitis, and other obstructive airway diseases. Bromhexine serves as a mucolytic agent, promoting the breakdown and clearance of viscous mucus from the respiratory tract, enhancing expectoration and improving airway patency. This synergistic combination provides both symptomatic relief from bronchoconstriction and effective mucus clearance, making it suitable for pediatric patients suffering from acute and chronic respiratory disorders. Grilinctus-BM Paediatric Syrup should be administered as directed by a healthcare professional, with dosage adjusted according to the child’s age and clinical condition. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. Common adverse effects may include mild gastrointestinal disturbances or nervous system symptoms. Proper use of Grilinctus-BM Paediatric Syrup can significantly improve respiratory function and patient comfort in pediatric respiratory illnesses.